ANDA 91244, held by Hikma Farmaceutica. Testosterone Cypionate.
As of Nov 16, 2026, ANDA 91244 (Testosterone Cypionate), held by Hikma Farmaceutica, was first approved by FDA on May 1, 2012, with 8 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency, or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 1, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Testosterone Cypionate200MG/ML · injectable;injection | Testosterone Cypionate | Rx |
| Jul 11, 2025 | Supplement 23Labeling · Standard review | Approved | None posted |
| Jul 9, 2025 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jul 9, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 27, 2017 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 26, 2016 | Supplement 2 | Approved | None posted |
| Jul 22, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 11, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 19, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 1, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters